Copyright
©The Author(s) 2021.
World J Gastroenterol. May 21, 2021; 27(19): 2281-2298
Published online May 21, 2021. doi: 10.3748/wjg.v27.i19.2281
Published online May 21, 2021. doi: 10.3748/wjg.v27.i19.2281
Figure 1 Treatment recommendations based on liver fibrosis severity in metabolic dysfunction-associated fatty liver disease patients.
HCC: Hepatocellular carcinoma; MAFLD: Metabolic dysfunction-associated fatty liver disease; NASH: Non-alcoholic steatohepatitis.
- Citation: Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298
- URL: https://www.wjgnet.com/1007-9327/full/v27/i19/2281.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i19.2281